close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

436.38 -9.41 (-2.11%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
20 21 Next >
News headline image
Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers ↗
 
Via Benzinga
News headline image
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Analyst Ratings for Alnylam Pharmaceuticals ↗
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: 
Via Benzinga
News headline image
Where Alnylam Pharmaceuticals Stands With Analysts ↗
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: 
Via Benzinga
News headline image
Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why Alnylam Pharmaceuticals Shares Are Falling ↗
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares are trading lower by 4.97% to $212.18 Monday morning after the company announced a proposed offering of $900 million convertible 
Via Benzinga
News headline image
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Where Alnylam Pharmaceuticals Stands With Analysts ↗
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: 
Via Benzinga
News headline image
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Alnylam Shares Detailed Patisiran Data From Rare Disease Study ↗
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.  
Via Benzinga
News headline image
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Posts Mid-Stage Study Data From Regeneron-Partnered Kidney Disease Drug ↗
 
Via Benzinga
News headline image
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
News headline image
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know ↗
Moderna Inc (NASDAQ: MRNA) has  
Via Benzinga
News headline image
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Will Investors Notice Exciting Sign On Alnylam Pharmaceuticals Chart? ↗
  If history is any guide, there may be good fortune ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
News headline image
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,000 Today ↗
  Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 15 years by 9.06% on an annualized basis producing an average annual return of 16.5%. Currently, Alnylam... 
Via Benzinga
News headline image
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion ↗
Shares of Pfizer's rumored takeover target have rocketed for two days running. 
Via Investor's Business Daily
News headline image
Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug ↗
The company will compete with Pfizer, which already has an approved drug. 
Via Investor's Business Daily
News headline image
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned ↗
Intellia is backing off the higher dose of a gene-editing drug in cardiomyopathy patients. 
Via Investor's Business Daily
News headline image
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review ↗
The Nasdaq and small caps rose while the S&P 500 is hitting resistance. 
Via Investor's Business Daily
News headline image
Alnylam Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗
Alnylam Pharmaceuticals (NASDAQ:ALNY) brought in sales totaling $224.82 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 15.42%, resulting in a loss of $277.40... 
Via Benzinga
News headline image
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday ↗
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. 
Via Benzinga
News headline image
Moderna, PayPal And Some Other Big Gainers From Wednesday ↗
U.S. stocks closed higher on Wednesday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
News headline image
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today? ↗
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran. 
Via InvestorPlace
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today